The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 1, 2005, Pages 27-33

  Parnham, Michael J ^a   Bogaards, J J P ^b   Schrander, F ^b   Schut, M W ^b   Oreskovic K ^a   Mildner, B ^a  

^a PLIVA Research Institute Ltd   (Croatia)

^b TNO   (Netherlands)

Author keywords

Cytochrome P450; Metabolism; PLD 118

Indexed keywords

2 AMINO 4 METHYLENECYCLOPENTANECARBOXYLIC ACID; ALPHA NAPHTHOFLAVONE; AMINO ACID; ANTIFUNGAL AGENT; BUFURALOL; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DICLOFENAC; DIETHYLDITHIOCARBAMIC ACID; ETHOXYRESORUFIN; KETOCONAZOLE; MEPHENYTOIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B6; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESORUFIN; SULFAPHENAZOLE; TESTOSTERONE; UMBELLIFERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; CANDIDIASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERIVATIZATION; DOG; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME STABILITY; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER HOMOGENATE; LIVER MICROSOME METABOLISM; NONHUMAN; RAT; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CYCLOLEUCINE; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROSOMES, LIVER; RATS; RIBOSOMAL PROTEINS;

EID: 13444283953     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.429     Document Type: Article

References (11)

1. Moossavi M, Bagheri B, Scher RK. Systemic antifungal therapy Dermatol Clin 2001; 19: 35-52.
2. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokin 2000; 38: 111-180.
3. Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 2001; 40: 441-472.
4. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-1558.
5. Ziegelbauer K, Babczinski P, Schönfeld W. Molecular mode of action of the antifungal β-amino acid BAY- 108888. Antimicrob Agents Chemother 1998; 42: 2197-2205.
6. Sorbera LA, Castaner J, Bozzo J. PLD-118. Antifungal isoleucyl t-RNA inhibitor. Drugs Fut 2002; 27: 1049-1055.
7. Parnham MJ, Schönfeld W. PLD-118: a novel antifungal for treatment of yeast infections: Animal pharmacokinetics. In Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Dec 16-19. American Society for Microbiology: Washington, D.C., 2001; Abstract F-2145.
8. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
9. Bogaards JJP, van Ommen B, van Bladeren PJ. Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol Appl Pharmacol 1995; 132: 44-52.
10. Bogaards JJP, Venekamp JC, van Bladeren PJ. The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. Chem Biol Interact 1996; 102: 169-182.
11. Bogaards JJP, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 30: 1131-1152.